Biogen Inc. plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.
Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study. The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday. Currently, there is no approved treatment in the United […]
NEWARK, Calif., Nov. 17, 2015 /PRNewswire/ — Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. and Canadian rights to cebranopadol and its related follow-on compound from Grünenthal GmbH (“Grünenthal”). Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive […]
Astellas obtains worldwide commercial rights to Chromocell’s novel, peripherally restricted NaV1.7 antagonist, CC8464 Chromocell receives $15 million in upfront payments and is eligible to receive over $500 million in development and commercial milestones plus double digit royalties on sales; additional development initiated by Chromocell could result in additional payments and co-promotion rights in the U.S. […]
Pfizer suffered a major setback in Britain on Thursday when the High Court in London ruled that claims of patent protection for the use of its $5 billion-a-year drug Lyrica as a pain treatment were invalid. Lyrica, known generically as pregabalin, was originally developed for epilepsy. However, further research showed it could also help […]